Last edition
News about "Duchenne muscular dystrophy (DMD) "
Del-Brax from Novartis Achieves Primary Biomarker Endpoint in FSHD Study
Novartis reported positive phase 1/2 FORTITUDE study results for delpacibart braxlosiran (del-brax) in FSHD, meeting primary and key secondary biomarker endpoints. The therapy could become the first disease-modifying treatment for FSHD, with a phase 3 trial underway.
Duchenne Muscular Dystrophy (DMD) | 12/06/2026 | By News Bureau
Zydus Receives USFDA Approval for Deflazacort Oral Suspension
Zydus stated that deflazacort oral suspension will be produced at Doppel, Italy.
Duchenne Muscular Dystrophy (DMD) | 06/10/2025 | By Dineshwori | 189
Santhera Partners with Ikris Pharma Network for Distribution of AGAMREE in India
Swiss specialty pharma company Santhera Pharmaceuticals has entered into an exclusive agreement with Ikris Pharma Network to distribute AGAMREE (vamorolone) in India for the treatment of Duchenne muscular dystrophy (DMD) in patients aged four years and above.
Duchenne Muscular Dystrophy (DMD) | 29/08/2025 | By Dineshwori | 457
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy